# US 2019/0376144 A1 · Diagnosis, prognosis and treatment of acute myeloid leukemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376144 A1
- Document ID: US20190376144A1
- Status: Published application
- Kind: A1
- Application number: 16/425,848
- Filed: 2019-05-29
- Published: 2019-12-12
- Earliest claimed: 2016-11-30
- Applicants: Onconostic Technologies, Inc.
- Inventors: Partha S. RAY
- Web page: https://patentgrep.com/patent/US20190376144A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57505: of the blood, e.g. leukaemia
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein is a method of screening AML patients who are unlikely to respond to or are not responsive to induction chemotherapy. The method includes detecting the expression level of FOXC1 in a sample obtained from the AML patient, and an elevated expression level indicates that the AML patient is unlikely to respond to or is not responsive to induction chemotherapy. Also disclosed herein is a method of treating AML patients who are unlikely to respond to or are not responsive to induction chemotherapy. The method includes detecting the expression level of FOXC1 in a sample obtained from the AML patient, and administering a therapeutically effective amount of one or more alternative therapies to the AML patient who has an elevated level of FOXC1 expression. The alternative therapy includes, for example, stem cell transplantation, radiotherapy, or a targeted therapy.

## Claims

### Claim 1

A method of screening for an AML patient who is unlikely to respond to or is non-responsive to induction chemotherapy, the method comprising:
determining the expression level of FOXC1 in a sample obtained from the patient, wherein an elevated level of FOXC1 expression indicates that the patient is unlikely to respond to or is non-responsive to induction chemotherapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is a tissue sample or a body fluid sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is a bone marrow sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the sample is a blood sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the AML patient has been subjected to induction chemotherapy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the AML patient has been diagnosed with AML but has not been subjected to induction therapy.

### Claim 7

A method of treating an AML patient who is unlikely to respond to or who is non-responsive to induction chemotherapy, the method comprising:
detecting the expression level of FOXC1 from a sample obtained from an AML patient; and
administering a therapeutically effective amount of one or more alternative therapies that is not chemotherapy to the patient who has an elevated level of FOXC1 expression.

### Claim 8 (depends on 7)

The method of claim 7, wherein the alternative therapy includes stem cell transplantation, radiotherapy, or a targeted therapy.

### Claim 9 (depends on 7)

The method of claim 7, wherein the sample is a tissue sample or a body fluid sample.

### Claim 10 (depends on 7)

The method of claim 7, wherein the sample is a bone marrow sample.

### Claim 11 (depends on 7)

The method of claim 7, wherein the sample is a blood sample.

### Claim 12 (depends on 7)

The method of claim 7, wherein the AML patient has been subjected to induction chemotherapy.

### Claim 13 (depends on 7)

The method of claim 7, wherein the AML patient has been diagnosed with AML but has not been subjected to induction chemotherapy.

### Claim 14 (depends on 7)

The method of claim 7, wherein the alternative therapy is stem cell transplantation, and the stem cells are autologous stem cells.

### Claim 15 (depends on 7)

The method of claim 7, wherein the alternative therapy is stem cell transplantation, and the stem cells are allogeneic stem cells.

### Claim 16

A method of treating an AML patient who is likely to respond to or who is responsive to induction chemotherapy, the method comprising:
detecting the expression level of FOXC1 from a sample obtained from an AML patient, and
administering a therapeutically effective amount of chemotherapy to the AML patient who does not have an elevated expression level of FOXC1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sample is a tissue sample or a body fluid sample.

### Claim 18 (depends on 16)

The method of claim 16, wherein the sample is a bone marrow sample.

### Claim 19 (depends on 16)

The method of claim 16, wherein the sample is a blood sample.
